The expanded approval makes enzalutamide the first and only approved androgen receptor signaling inhibitor in the nonmetastatic castration-sensitive prostate cancer setting.
Trastuzumab deruxtecan (T-DXd) provided sustained clinically meaningful improvement versus physician’s choice of treatment (TPC) for patients with advanced breast cancer and low HER2 expression.